Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 65
GHK-Cu injection nodule: what to know
A firm, painless lump at a GHK-Cu injection site lasting two weeks is usually a sterile tissue reaction. Here is what drives it and when to see a clinician.
PAD and GLP-1 drugs: the 2026 evidence
A 2026 European Heart Journal review names semaglutide as the only anti-obesity drug shown to cut cardiovascular events in high-risk patients without diabetes.
Semaglutide TBI study: blood-brain barrier
A 2026 mouse study found semaglutide promoted angiogenesis and blood-brain barrier repair after traumatic brain injury via a PDGF-BB/PDGFRbeta/VEGF cascade.
TB-500 in Sweden: regulatory status 2026
TB-500 has no authorisation from Läkemedelsverket or the EMA. Here is how Swedish law classifies it and what changed.
Wolverine stack for shoulder and elbow pain
BPC-157 and TB-500 have animal data on tendon healing but no human trials for shoulder or elbow injury. Here is what the research actually shows.
Bariatric surgery volumes fell 39%
Epic Cosmos data show US bariatric surgery peaked in Q4 2022 and fell 39% by Q4 2025. Access to GLP-1 agonists before surgery splits sharply by insurance.
BPC-157 and night sweats: what we know
Night sweats appear in BPC-157 user reports but not in any published study. Here is what the evidence and the likely mechanism actually show.
GLP-1 RAs in aging people with HIV
A 2026 review finds semaglutide reduces weight, improves cardiometabolic markers, and may slow epigenetic aging in people with HIV, but key safety gaps remain.
GLP-1R G protein bias via ECL3 displacement
A July 2026 Cell Reports study shows N-terminal modifications to GLP-1R agonists shift signalling toward G protein by displacing extracellular loop 3.
Semaglutide, NAION, and a retracted study
A 2025 paper in Retina on semaglutide and optic nerve risk has been retracted without a stated reason, complicating an already contested safety debate.
Skin Growths, Sermorelin, and BPC-157/TB500
Community reports link sermorelin and BPC-157/TB-500 use to acanthosis. Here is what the IGF-1 and skin-biology literature actually shows.
T2D and obesity: why treatment falls short
A July 2026 expert review finds clinicians undertreat obesity in type 2 diabetes, leaving a key driver of glycaemic failure and cardiovascular risk unaddressed.